Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 28, 2011

BioFocus to Offer Screening and Profiling Services Based on Almac’s Flexyte FLT Platform

  • BioFocus and Almac have inked an agreement that will allow BioFocus to offer its customers compound screening and profiling services using Almac’s Flexyte™ fluorescence lifetime (FLT) assays. The firm has launched an FLT screening and profiling service using the Flexyte platform, for targets including proteases, phosphatases, and kinases. It says the Flexyte platform can be exploited for applications including fragment-based screens and kinetic profiling.

    “Being able to incorporate FLT in our service offering enables BioFocus to provide clients with an approach to screening and profiling that will unlock significant potential within their drug discovery efforts,” comments Kate Hilyard, vp biological sciences.

    Almac claims the Flexyte approach harnesses fluorescence lifetime technology that negates the need for radioactivity and antibodies, to enable robust and reliable assays that can be miniaturized and multiplexed.  



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »